Jiangsu Hengrui Medicine Co., Ltd.
https://www.hrs.com.cn/index.html
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hengrui Medicine Co., Ltd.
Stock Watch: When Governments Step In
Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.
2021 Marked New Era Of Domestic Collaboration in China
Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.
Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
Hengrui Takes Focused Approach Amid China Inc's Global Drive
China’s largest innovative domestic drug maker will only take global those products that play into its strengths, chairman Piaoyang Sun declares.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd.